VEGA Prospective Kiel

N/ACompletedNCT02802085

Aesculap AG84 enrolled

Overview

Voluntary Post-Marketing Clinical Follow-up (PMCF) as part of the post marketing surveillance plan for the product under investigation. For this PMCF only CE-marked medical devices have been used and will be used within their intended purpose and no additional invasive or other stressful examinations have been or are to be carried out (acc. to MPG §23b).

This non-interventional clinical study (NIS) is conducted to clinically confirm the safety and performance of the Aesculap® VEGA System® PS components under routine conditions. The VEGA System® PS is an established TKA design, and there is a long-lasting experience in the use of PS components in particular; thus a NIS is thought to be sufficient to give the required confirmation. For this NIS only CE-marked medical devices have been used and will be used within their intended purpose and no additional invasive or other stressful examinations have been and are to be carried out (acc. to MPG §23b). This voluntary NIS is part of the post-marketing surveillance for the product under investigation.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Degenerative Osteoarthritis Rheumatoid Arthritis

Interventions

VEGA KneeDEVICE

TKA

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patient has received primary TKA at the study site five to six years ago using the product under investigation because of the following severe knee joint conditions that could not be treated through other therapies: * degenerative osteoarthritis, * rheumatoid arthritis, * posttraumatic arthritis, * symptomatic knee instability, knee stiffness or deformation of the knee joint * Age at the time of surgery ≥ 18 years * Patient signed informed consent Exclusion Criteria: * Age younger than 18 years at the time of surgery * Any prior joint replacement at the index knee * Patient did not sign informed consent * All cases not listed under indications (according to IfU) * All cases showing any contraindication (according to IfU)

Locations (1)

MEDBALTIC GmbH c/o Mare Klinikum

Kiel, Germany

Outcomes

Primary Outcomes

Revision (non-survival) rate

The objective of the study is to collect clinical 5 year outcome information on the product under investigation when used in routine clinical practice.

Time frame: 5 years

Secondary Outcomes

Knee injury and Osteoarthritis Outcome Score (KOOS)

Changes of the total Knee injury and Osteoarthritis Outcome Score (KOOS) from the preoperative baseline to the 5 year postoperative assessment

Time frame: 5 years

Physical Component Summary (PCS-12) of SF-12® Health Survey (SF-12)

Changes of the total SF-12® Health Survey (SF-12) from the preoperative baseline to the 5 year postoperative assessment

Time frame: 5 years

Mental Component Summary (MCS-12) of SF-12® Health Survey (SF-12)

Changes of the total SF-12® Health Survey (SF-12) from the preoperative baseline to the 5 year postoperative assessment

Time frame: 5 years

Pain

Changes of anterior knee pain according to the Waters and Bentley rating system from the preoperative baseline to the 5 year postoperative assessment

Time frame: 5 years

Knee Score (KS) of Knee Society Score (KSS)

The Knee Score (KS) of the Knee Society Score (KSS) at the 5 year postoperative assessment

Time frame: 5 years

Functional Score (FS) of Knee Society Score (KSS)

The Functional Score (FS) of the Knee Society Score (KSS) at the 5 year postoperative assessment

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.